0Q77.L
AB SCIENCE SA AB SCIENCE ORD SH
£0.96
-0.41%
2026-06-01
About AB SCIENCE SA AB SCIENCE ORD SH
AB Science S.A., a clinical-stage company, engages in the research, design, development, and marketing of drugs to address pathologies affecting the peripheral and central nervous system, inflammatory diseases, and cancers in France. The company's lead drug candidate is masitinib, a selective protein kinase inhibitor that targets mast cells and microglia in Phase 3 trial for the treatment of amyotrophic lateral sclerosis, progressive forms of multiple sclerosis, Alzheimer's disease, and indolent systemic mastocytosis, as well as in Phase 2 trial for mast cell activation syndrome and sickle cell disease. It also develops AB8939, a microtubule destabilizer in Phase 1 trial for the treatment of acute myeloid leukemia; and AB12319 in preclinical trial to treat sarcoma and solid tumors. In addition, the company markets its masitinib under the Masivet brand for the treatment of mast cell tumors in dogs in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.
Key Fundamentals
EPS (TTM)
£-0.30
Revenue Growth (YoY)
28.7%
Profit Margin
-132.6%
Price/Book
-2.35
Beta
1.18
Market Cap
£46.7M
Avg Volume (10D)
7K
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
£1.43
60D Low
£0.94
Avg Volume
3K
Latest Close
£0.96
Get breakout alerts for 0Q77.L
Sign up for Breakout Scanner to receive daily notifications when 0Q77.L triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial.
AB SCIENCE SA AB SCIENCE ORD SH (0Q77.L) is listed on the London Stock Exchange (LSE). Breakout Scanner monitors 0Q77.L daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups.. Data is provided for informational purposes only and does not constitute financial advice.